AZN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AstraZeneca PLC (AZN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent price declines, the stock has strong positive catalysts, favorable analyst ratings, and a promising growth outlook, making it an attractive entry point for long-term gains.
The stock is currently trading below key pivot levels, with MACD showing a negative expansion (-0.369) and RSI at 32.685, indicating a potential oversold condition. Moving averages are converging, suggesting a neutral trend. Key support levels are at 175.154 and 172.212, with resistance at 179.916 and 184.677.
FDA priority review status for a new drug, expediting approval and boosting future revenue.
FDA approval of Truqap for PTEN-deficient metastatic prostate cancer, a significant milestone in oncology.
Positive analyst sentiment, with multiple Buy ratings and price target increases.
Promising mid-stage data on GLP-1 drugs, indicating potential market entry by 2029.
Recent FDA committee vote against camizestrant SERENA-6, although this is not a significant part of the company's growth thesis.
Regular market price decline of -1.66%, indicating short-term bearish sentiment.
No financial data available for analysis.
Analysts maintain a strong Buy consensus with multiple price target increases. Jefferies, DZ Bank, Citi, Morgan Stanley, Goldman Sachs, and Guggenheim have all issued Buy ratings recently, citing strong pipeline developments, oncology growth, and positive catalysts.
